Who ChondroFiller is for — and who it isn't

Not everyone with hip pain is a candidate for ChondroFiller, and being clear about that upfront saves time on both sides of the consultation.

The treatment is designed for patients who have identifiable hip cartilage damage confirmed on MRI — typically a focal Grade III or IV defect, or more widespread wear classified as Kellgren-Lawrence Grade III or IV osteoarthritis. Younger, more active patients with a contained area of damage tend to respond well, because there is enough surrounding tissue to support the scaffold and seed the repair. Patients with diffuse but not yet end-stage wear can also be assessed, since the injectable format allows the collagen gel to coat broader surface areas rather than targeting a single discrete lesion.

Two situations make ChondroFiller unsuitable. Active infection inside the hip joint is an absolute contraindication — no cartilage scaffold can integrate safely in an infected environment. End-stage hip arthritis, where cartilage has been lost so completely that there is no viable surface left for the gel to bond to, is equally unsuitable; in those cases, joint replacement is the more appropriate conversation.

Critically, this is not a walk-in injection. An MRI scan is required before any treatment decision is made. At Lincolnshire Hip, Professor Paul Lee reviews the imaging personally to map the cartilage defect, grade its severity, and determine whether the anatomy supports scaffold placement. That review forms the basis of a written treatment plan agreed with the patient before anything else is scheduled.

Lincolnshire Hip accepts patients without a GP referral for hip assessment, so the starting point for most people is the suitability self-assessment tool on the site, followed by a consultation at the Grantham or Sleaford clinic.

Before the injection: MRI, cartilage mapping, and treatment planning

The one-hour consultation at Grantham or Sleaford is where the planning work is done. Imaging is assessed in detail: the cartilage defect is located within the hip joint, its depth graded, and its surface area estimated. That mapping matters because ChondroFiller is delivered directly into the damaged site under ultrasound guidance — the precision of the injection depends on knowing exactly where and how large the defect is before the appointment begins.

The consultation also covers outcome expectations in concrete terms. The collagen scaffold works by recruiting the body's own repair cells over three to twelve months; this is not a treatment that produces immediate pain relief, and discussing that timeline honestly is a deliberate part of the process. Patients leave with a clear understanding of what the early weeks of protected loading involve and when measurable change is typically detectable on follow-up MRI.

The appointment closes with a written treatment plan that includes the proposed injection date, the protected-loading schedule for the first four to six weeks, and a six-week follow-up review. That plan is agreed before anything is booked — the structured sequence is intentional, because accurate placement of the scaffold depends on the preparation that precedes it.

What happens during the injection appointment

On the day of the injection, the appointment fits into a single outpatient session — no operating theatre, no general anaesthetic, and no overnight stay required.

The first step is a short-acting local anaesthetic injected into the skin and soft tissue around the hip to numb the area. Most patients describe a brief stinging sensation that settles within a minute or two, after which the hip feels sufficiently dulled for the procedure to proceed comfortably.

With the area anaesthetised, the clinician uses live ultrasound imaging to guide the needle to its precise position inside the hip joint. Because the hip is a deep ball-and-socket joint, that real-time picture is essential — it allows the clinician to visualise surrounding soft tissues and neurovascular structures as the needle advances, confirming accurate intra-articular placement without any ionising radiation. This is the same principle that makes ultrasound-guided injection suitable for a clinic setting rather than a theatre.

Once the needle is correctly positioned, the ChondroFiller collagen solution is injected into the joint space. It begins to polymerise within three to five minutes of contact with the joint environment, forming a stable scaffold directly over the worn cartilage surface. Intravenous antibiotic cover is administered as part of the appointment protocol to reduce infection risk.

The overall session is typically under an hour. Patients can walk out of the clinic immediately afterwards, though a driver is advisable — the hip may feel temporarily heavy or stiff as the local anaesthetic wears off, and most people find it easier not to drive on the day of treatment.

How the collagen scaffold works once it's in the hip joint

Unlike a steroid or hyaluronic acid injection — both of which act on arrival and begin to wear off within weeks — ChondroFiller works on a fundamentally different timescale, and understanding that distinction is central to realistic expectations of the treatment.

ChondroFiller is not a drug. It is a CE-marked Class III medical device: an acellular gel composed of murine-derived Type I collagen, the same structural protein that forms the backbone of healthy cartilage. Once bonded to the damaged surface of the hip joint, the biological work begins in earnest.

The mechanism is what specialists term acellular matrix-induced chondrogenesis — in plain terms, the scaffold encourages the body's own cells to migrate in and begin repair. Progenitor cells drawn from the synovium and subchondral bone are chemotactically recruited into the collagen matrix over the first days to weeks. Finding a structured environment within the scaffold, they differentiate into chondrocytes — the cells responsible for producing cartilage-like tissue — and over the following three to twelve months begin laying down fibrocartilage-like repair tissue within the defect.

The scaffold itself does not remain in the joint indefinitely. By one to two years after injection, the collagen matrix is fully resorbed and replaced by the patient's own repair tissue; nothing foreign is left in the hip joint long-term. That resorption is a deliberate design feature rather than a limitation — the scaffold performs its structural and chemotactic role and then steps aside.

This biological sequence is why outcomes are tracked at six and twelve months using the Harris Hip Score and MOCART MRI, and why patients are counselled not to expect the immediate symptomatic shift associated with a corticosteroid or viscosupplement appointment. The repair process requires time; measurable change on imaging typically emerges well into the programme rather than in the days following the clinic visit.

The first six weeks: protected loading and what to avoid

Protected loading — the term used to describe the first four to six weeks after the injection — is perhaps the most important practical concept for patients to understand before booking.

The phrase does not mean bed rest. Most patients can manage stairs, light walking, and desk-based work within a day or two. What the protected phase rules out is sustained high-impact load on the hip: running, prolonged standing, heavy lifting, and anything that transmits sharp repetitive force through the joint. The reason is biological rather than precautionary caution — the collagen scaffold needs an undisturbed environment for early cell recruitment to begin, and excessive load during this window risks disrupting that process before the matrix has properly bonded and populated.

A six-week follow-up review is built into the pathway at Lincolnshire Hip. That appointment is when Professor Lee assesses early progress, reviews symptoms, and updates activity guidance based on individual response — so activity restrictions are not simply imposed for six weeks and then lifted without reassessment.

The detailed rehabilitation guidance developed for Liquid Cartilage™ was produced primarily around the surgical delivery route, which involves a lengthier operative recovery. For the ultrasound-guided injection pathway, the overall burden is considerably lower — but that should not be taken to mean the protected phase is trivial. Six weeks is a real commitment, and patients with physically demanding jobs, active carer responsibilities, or mobility dependencies should raise those circumstances at consultation so a realistic activity plan can be agreed in advance.

When results appear and how progress is measured

Tissue formation is a gradual process: the period of most active repair runs from roughly three to six months after the injection, and meaningful clinical benefit is typically assessed at twelve months rather than in the early weeks.

At Lincolnshire Hip, two tools frame that assessment. The Harris Hip Score is a patient-reported measure of hip function — covering pain, mobility, and daily activity — that provides a comparable number before and after treatment. MOCART MRI evaluates the quality and fill of repair tissue within the defect on imaging, giving an objective picture that complements what the patient reports. Both are reviewed at the six-month and twelve-month follow-up appointments built into the pathway.

Published ChondroFiller data — drawn from investigations spanning both arthroscopic and injectable delivery routes — shows IKDC scores improving by approximately 30 points at twelve months; hip-specific modified Harris Hip Score data shows improvement of similar magnitude. That origin matters when reading the numbers: long-term randomised controlled trial data specific to the ultrasound-guided hip injection route alone is still accumulating, and the published figures reflect a combined evidence base rather than one delivery method in isolation. Within that context, the safety profile is encouraging — a complication rate of approximately 0% and a reoperation rate of roughly 3–8%, compared with reoperation rates of up to 41% for microfracture and up to 37% for ACI/MACI.

Patients should be prepared for a measured timeline. The scaffold begins its biological work from the day of injection, but the first weeks bring no dramatic symptomatic shift — meaningful change on imaging and in reported function typically emerges well into the first year.